Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
Yvonne Tan, Maya H Buch
RMD Open (2022) Vol. 8, Iss. 2, pp. e002387-e002387
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis
Antonios Bertsias, Irini Flouri, Argyro Repa, et al.
RMD Open (2024) Vol. 10, Iss. 1, pp. e003808-e003808
Open Access | Times Cited: 11
Multi-therapeutic potential of flavonoids as an essential component in nutraceuticals for the treatment and management of human diseases
Stanley I.R. Okoduwa, Ibrahim Abdulwaliyu, Bernard E. Igiri, et al.
Phytomedicine Plus (2024) Vol. 4, Iss. 2, pp. 100558-100558
Open Access | Times Cited: 10
Difficult-to-treat rheumatoid arthritis: Current concept and unsolved problems
Ryu Watanabe, Tadashi Okano, Takaho Gon, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 34
Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
Leticia León, Alfredo Madrid-García, Patricia Lopez-Viejo, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002842-e002842
Open Access | Times Cited: 16
Glucocorticoid-loaded pH/ROS dual-responsive nanoparticles alleviate joint destruction by downregulating the NF-κB signaling pathway
Yanzhu Lu, Jiangling Zhou, Qianmei Wang, et al.
Acta Biomaterialia (2023) Vol. 164, pp. 458-473
Closed Access | Times Cited: 15
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender
Nicoletta Luciano, Elisa Barone, Enrico Brunetta, et al.
Arthritis Research & Therapy (2025) Vol. 27, Iss. 1
Open Access
Rheumatoid arthritis severity is mediated by crosstalk between synoviocytes and mature osteoclasts through a calcium and cytokine feedback loop
Eun Sun Lee, Hyeong Jae Kim, Dongun Lee, et al.
Experimental & Molecular Medicine (2025)
Open Access
Effects of nutritional supplements and dietary interventions on rheumatoid arthritis: An umbrella review of meta-analyses of randomized controlled trials
Xueer Cheng, Xiao Hu, Jian Tang, et al.
Autoimmunity Reviews (2025) Vol. 24, Iss. 6, pp. 103792-103792
Closed Access
Extracellular vesicle as a next-generation drug delivery platform for rheumatoid arthritis therapy
Yi Jin, Cong Xu, Yujuan Zhu, et al.
Journal of Controlled Release (2025) Vol. 381, pp. 113610-113610
Closed Access
Poly‐Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes
Paula David, Andrea Di Matteo, Or Hen, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 4, pp. 510-521
Open Access | Times Cited: 15
Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital
Sophie Hecquet, Alice Combier, Alexia Steelandt, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 12, pp. 3866-3874
Closed Access | Times Cited: 14
Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Rheumatology and Therapy (2023) Vol. 10, Iss. 5, pp. 1119-1125
Open Access | Times Cited: 13
A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management
Carly Conran, Jason R. Kolfenbach, Kristine A. Kuhn, et al.
Current Rheumatology Reports (2023) Vol. 25, Iss. 12, pp. 285-294
Closed Access | Times Cited: 12
Is the Difficult-to-Treat (D2T) concept applicable to axial spondyloarthritis?
Daniel Wendling, Frank Verhoeven, Clément Prati
Joint Bone Spine (2022) Vol. 90, Iss. 3, pp. 105512-105512
Closed Access | Times Cited: 19
Inflammation‐Targeting Mesenchymal Stem Cells Combined with Photothermal Treatment Attenuate Severe Joint Inflammation
Min Jun Shin, Jun‐Young Park, Jun Young Park, et al.
Advanced Materials (2023) Vol. 36, Iss. 11
Closed Access | Times Cited: 11
The protective effect of natural medicines in rheumatoid arthritis via inhibit angiogenesis
Chang Gao, Xiaodi Song, Fanghui Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease
Е. Л. Насонов, А. С. Авдеева, Д. А. Дибров
Rheumatology Science and Practice (2023) Vol. 61, Iss. 3, pp. 276-291
Open Access | Times Cited: 9
Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations
Rodrigo García Salinas, Einer Sanchez-Prado, Jonatan Mareco, et al.
Rheumatology International (2023) Vol. 43, Iss. 10, pp. 1821-1828
Closed Access | Times Cited: 8
Management of Rheumatoid Arthritis in Primary Care: A Scoping Review
Francesco Inchingolo, Angelo Michele Inchingolo, Maria Celeste Fatone, et al.
International Journal of Environmental Research and Public Health (2024) Vol. 21, Iss. 6, pp. 662-662
Open Access | Times Cited: 2
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Ju‐Yang Jung, Eunyoung Lee, Ji-Won Kim, et al.
Arthritis Research & Therapy (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis
Marta Novella-Navarro, Virginia Ruiz‐Esquide, Natalia López-Juanes, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 9, pp. 2817-2823
Closed Access | Times Cited: 2
Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra)
Е. Л. Насонов, Z. N. Sukmarova, Т. В. Попкова, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 1, pp. 47-61
Open Access | Times Cited: 6
Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
Marta Novella-Navarro, José Luis Cabrera-Alarcón, Natalia López-Juanes, et al.
RMD Open (2023) Vol. 9, Iss. 3, pp. e003382-e003382
Open Access | Times Cited: 6
Inflammation-Responsive Mesoporous Silica Nanoparticles with Synergistic Anti-inflammatory and Joint Protection Effects for Rheumatoid Arthritis Treatment
Ye-zhen Wu, Wenyu Chen, Ying Zeng, et al.
Pharmaceutical Research (2024) Vol. 41, Iss. 7, pp. 1493-1505
Closed Access | Times Cited: 1
The role of interleukin 17 in the pathogenesis of rheumatoid arthritis. Are there any prospects for the use of IL-17 inhibitors?
Е. Л. Насонов, А. С. Авдеева, Т. В. Коротаева, et al.
Rheumatology Science and Practice (2023) Vol. 61, Iss. 2, pp. 165-180
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top